Survival and causes of death in children diagnosed with cancer in Iceland 1981-2006

Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn Skoða/Opna(view/open)OBJECTIVE: Of children diagnosed with cancer, approximately one fourth die of the disease or disease related complications. The aim of this study was to investigate survival and causes of death in children with cancer in Iceland. METHODS: This study is retrospective; population based and includes all children, less than 18 years of age, diagnosed with cancer in Iceland from 1981 to 2006. Information was extracted from the Icelandic Cancer Registry, patients hospital records and data from Statistics Iceland. RESULTS: Of 279 children diagnosed with cancer in the research period 215 were alive at the end of 2008. The overall 5-year survival was 81.2% and 10-year survival was 76.7%. There was not a significant survival difference with respect to age at diagnosis, year of diagnosis, gender or geographical residence. The small cohort size could be the explanation. Eleven individuals developed secondary neoplasm, eight of whom died. Sixteen of the 64 nonsurvivors were treated with curative intent until death, 12 of them died of therapy related complications. CONCLUSIONS: Survival rate in childhood cancer in Iceland is comparable to other Western countries. As previously reported, prognosis of patients with secondary neoplasm is unfavorable. Therapy related complications are the most common cause of death in patients treated with curative intent.Inngangur: Um fjórðungur barna sem greinist með krabbamein deyr vegna sjúkdóms síns eða meðferðartengdra fylgikvilla. Tilgangur rannsóknarinnar var að kanna lifun og dánarorsakir barna sem greinst hafa með krabbamein á Íslandi. Aðferðir: Rannsóknin var afturskyggn, lýðgrunduð og náði til allra einstaklinga yngri en 18 ára sem greindust með krabbamein á Íslandi frá upphafi árs 1981 til loka ársins 2006. Upplýsingum var safnað frá Krabbameinsskrá Íslands, sjúkraskrám og Hagstofu Íslands. Niðurstöður: Á rannsóknartímabilinu greindust 279 börn með krabbamein á Íslandi. Af þeim voru 215 á lífi í lok árs 2008. Á tímabilinu var fimm ára lifun 81,2% og 10 ára lifun 76,7%. Ekki var marktækur munur á lifun milli kynja, greiningartímabila, aldurs eða búsetu. Gæti það skýrst af smæð þýðisins. Lifun var mismunandi eftir krabbameinstegundum. Ellefu einstaklingar greindust síðar með meðferðartengd krabbamein, átta þeirra létust. Sextán þeirra 64 sem létust voru í læknandi meðferð fram að andláti. Var dánarorsök meðferðartengdir fylgikvillar hjá 12 úr þeim hópi. Ályktun: Horfur barna og unglinga á Íslandi með krabbamein eru sambærilegar við önnur vestræn ríki. Horfur eru mun verri í meðferðartengdum krabbameinum samanborið við frumkrabbamein. Meðferðartengdir fylgikvillar eru algengasta dánarorsök ef krabbameinsmeðferð er gefin með læknanlegum tilgangi

Childhood cancer in Iceland 1981-2006

Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn Skoða/Opna(view/open)BACKGROUND: Childhood cancer is the second most common cause of death in children. The aim of this study was to gather epidemiological information on childhood cancer in Iceland. METHODS: The study was population based and included all children younger than 18 years of age, diagnosed with cancer in Iceland from 1981 to 2006. Information was extracted from the Icelandic Cancer Registry and patient hospital records. RESULTS: During the study period 288 cancer cases were diagnosed in 279 children, 10 cases were secondary neoplasms. Age standardized incidence was 16.1 per 100.000 (95% CI 13,6-18,6) for boys and 12.8 per 100.000 (95% CI 10,5-15,0) for girls. There was no significant difference in the incidence rate between the first and second half of the study period. For children aged 0-14 years, the age standardized incidence was 13.6 per 100.000. The incidence was highest in the 0-4 year age group (17.3 per 100.000) and in the 15-17 year age group (19.6 per 100.000). Brain tumors (27.1%) and leukemia (25.0%) were the most common cancer groups diagnosed. Lymphoid leukemia was the most common cancer type (17.9%) and astrocytoma (13.1%) came second. CONCLUSIONS: The incidence of childhood cancer in Iceland is similar to other Western countries. Long-term follow-up is very important in childhood cancer survivors.Inngangur: Krabbamein er næst algengasta dánarorsök barna á eftir slysum. Tilgangur rann-sóknarinnar var að kanna nýgengi krabbameina hjá börnum á Íslandi.
 Aðferðir: Rannsóknin var lýðgrunduð og náði til allra <18 ára sem greindust með krabbamein á Íslandi frá upphafi árs 1981 til ársloka 2006. Upplýsingum var safnað frá Krabbameinsskrá Íslands og úr sjúkraskrám.
 Niðurstöður: Alls greindust 288 krabbameinstilfelli á tímabilinu hjá 279 börnum. Í 10 tilvikum var um meðferðartengd krabbamein að ræða. Árlegt aldursstaðlað nýgengi hjá drengjum var 16,1 af 100.000 (95% CI; 13,6-18,6) en hjá stúlkum 12,8 af 100.000 (95% CI; 10,5-15,0) en ekki var marktækur munur á nýgengi milli fyrri og seinni hluta rannsóknartímabilsins. Fyrir aldursbilið 0-14 ára var árlegt aldursstaðlað nýgengi 13,6 af 100.000. Miðtaugakerfisæxli og hvítblæði voru samanlagt 52,1% allra krabbameinstilvika. Algengasta grein-ingin var bráða eitilfrumuhvítblæði (17,9%) og stjarnfrumnaæxli (13,1%) næstalgengust. Nýgeng-ið var hæst hjá aldursbilunum 0-4 ára (17,3 af 100.00) og 15-17 ára (19,6 af 100.000). Tíu börn voru með þekkta meðfædda áhættuþætti.
 Ályktun: Nýgengi krabbameina hjá börnum á Íslandi er sambærilegt við nágrannalöndin. Mikilvægt er að fylgja vel eftir börnum sem gengið hafa í gegnum krabbameinsmeðferð og þeim sem hafa þekkta meðfædda áhættuþætti.


The marginal cost of track renewals in the Swedish railway network: Using data to compare methods

We analyze the differences between corner solution and survival models in estimating the marginal cost of track renewals. Both approaches describe the renewal process in intuitively similar ways but have several methodological distinctions. Using Swedish data for the 1999–2016 period, results suggest the median marginal costs per gross ton-km from corner solution and survival models are SEK 0.0066 and SEK 0.0031, respectively. Since several European countries use information about marginal costs as a basis for track user charges, the choice of estimation method is obviously important. Our conclusion is that the corner solution model is more appropriate in this case, as this method considers the impact traffic has both on the probability of renewal and on the size of the renewal cost. The survival approach does not consider the latter as part of the estimations, which is problematic when we have systematic cost variations due to traffic and infrastructure characteristics

BRCA1 and BRCA2 mutations in a population-based study of male breast cancer

Background: The contribution of BRCA1 and BRCA2 to the incidence of male breast cancer (MBC) in the United Kingdom is not known, and the importance of these genes in the increased risk of female breast cancer associated with a family history of breast cancer in a male first-degree relative is unclear. Methods: We have carried out a population-based study of 94 MBC cases collected in the UK. We screened genomic DNA for mutations in BRCA1 and BRCA2 and used family history data from these cases to calculate the risk of breast cancer to female relatives of MBC cases. We also estimated the contribution of BRCA1 and BRCA2 to this risk. Results: Nineteen cases (20%) reported a first-degree relative with breast cancer, of whom seven also had an affected second-degree relative. The breast cancer risk in female first-degree relatives was 2.4 times (95% confidence interval [CI] = 1.4–4.0) the risk in the general population. No BRCA1 mutation carriers were identified and five cases were found to carry a mutation in BRCA2. Allowing for a mutation detection sensitivity frequency of 70%, the carrier frequency for BRCA2 mutations was 8% (95% CI = 3–19). All the mutation carriers had a family history of breast, ovarian, prostate or pancreatic cancer. However, BRCA2 accounted for only 15% of the excess familial risk of breast cancer in female first-degree relatives. Conclusion: These data suggest that other genes that confer an increased risk for both female and male breast cancer have yet to be found

Exposure of mediterranean countries to ocean acidification

This study examines the potential effects of ocean acidification on countries and fisheries of the Mediterranean Sea. The implications for seafood security and supply are evaluated by examining the sensitivity of the Mediterranean to ocean acidification at chemical, biological, and macro-economic levels. The limited information available on impacts of ocean acidification on harvested (industrial, recreational, and artisanal fishing) and cultured species (aquaculture) prevents any biological impact assessment. However, it appears that non-developed nations around the Mediterranean, particularly those for which fisheries are increasing, yet rely heavily on artisanal fleets, are most greatly exposed to socioeconomic consequences from ocean acidification. © 2014 by the authors; licensee MDPI, Basel, Switzerland

Ctenophore population recruits entirely through larval reproduction in the central Baltic Sea

The comb jelly Mertensia ovum, widely distributed in Arctic regions, has recently been discovered in the northern Baltic Sea. We show that M. ovum also exists in the central Baltic but that the population consists solely of small-sized larvae (less than 1.6 mm). Despite the absence of adults, eggs were abundant. Experiments revealed that the larvae were reproductively active. Egg production and anticipated mortality rates suggest a self-sustaining population. This is the first account of a ctenophore population entirely recruiting through larval reproduction (paedogenesis). We hypothesize that early reproduction is favoured over growth to compensate for high predation pressure

Role of Glomerular Proteoglycans in IgA Nephropathy

Mesangial matrix expansion is a prominent feature of the most common form of glomerulonephritis, IgA nephropathy (IgAN). To find molecular markers and improve the understanding of the disease, the gene and protein expression of proteoglycans were investigated in biopsies from IgAN patients and correlated to clinical and morphological data. We collected and microdissected renal biopsies from IgAN patients (n = 19) and from healthy kidney donors (n = 14). Patients were followed for an average time of 4 years and blood pressure was according to target guidelines. Distinct patterns of gene expression were seen in glomerular and tubulo-interstitial cells. Three of the proteoglycans investigated were found to be of special interest and upregulated in glomeruli: perlecan, decorin and biglycan. Perlecan gene expression negatively correlated to albumin excretion and progress of the disease. Abundant decorin protein expression was found in sclerotic glomeruli, but not in unaffected glomeruli from IgAN patients or in controls. Transforming growth factor beta (TGF-β), known to interact with perlecan, decorin and biglycan, were upregulated both on gene and protein level in the glomeruli. This study provides further insight into the molecular mechanisms involved in mesangial matrix expansion in IgAN. We conclude that perlecan is a possible prognostic marker for patients with IgAN. In addition, the up-regulation of biglycan and decorin, as well as TGF-β itself, indicate that regulation of TGF-β, and other profibrotic markers plays a role in IgAN pathology